All In MedTech

Device Trial Radar · NCT00387803

Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation

VENTAK CHF/CONTAK CD Biventricular Pacing Study

Last checked: Nov 20, 2026Latest source record: Jan 25, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 581 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

581

Actual

Start

Feb 1998

Primary completion

Not stated

Study completion Aug 2001

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
First posted
Oct 13, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.

Conditions

  • Heart Failure, Congestive
  • Ventricular Fibrillation
  • Tachycardia, Ventricular

Interventions

  • Cardiac Resynchronization Therapy with DefibrillationDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of all-cause mortality, heart failure hospitalization, and ventricular tachyarrhythmia

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Multiple locations

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.